MONTE ROSA THERAPEUTIC

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

28 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

19 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

08 8 2024 07:00:02 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

08 7 2024 08:36:57 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

27 6 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

14 6 2024 08:45:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Leadership Team Promotions

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

30 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

21 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

16 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

15 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 5 2024 07:00:01 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

02 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

14 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

11 3 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

31 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024

08 1 2024 07:15:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 1 2024 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

21 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

09 11 2023 07:00:00 提供 Nasdaq GlobeNewswire